Share This Page
Drug Price Trends for NDC 68084-0947
✉ Email this page to a colleague
Average Pharmacy Cost for 68084-0947
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68084-0947
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 68084-0947
Overview of NDC 68084-0947
National Drug Code (NDC) 68084-0947 identifies a specific pharmaceutical product manufactured and distributed within the United States. As of recent data, this code corresponds to an innovative biologic or specialty medication targeted at multidimensional therapeutic areas, often involving complex or high-cost treatments such as oncology, autoimmune diseases, or rare disorders. Because NDC details are proprietary and subject to manufacturer confidentiality, precise data may vary but typically involve therapeutics with high development costs, specialized administration, and limited market competition.
Market Landscape
Therapeutic Area and Clinical Demand
Historically, drugs associated with NDCs similar to 68084-0947 operate in lucrative, high-growth markets. For example, if this NDC pertains to a biologic in oncology, the global cancer drug market surpassed USD 130 billion in 2021, driven by increasing incidence rates and novel therapies [1]. Meanwhile, drugs targeting autoimmune conditions such as rheumatoid arthritis or psoriatic arthritis also show consistent growth owing to expanding patient populations and advancements in biologic therapies.
Market Drivers
- Rising Prevalence of Target Diseases: The increase in chronic and complex diseases directly affects demand.
- Innovation in Biologics & Biosimilars: Patent expirations foster opportunities for biosimilar competition, influencing pricing.
- Regulatory Policies: Favorable reimbursement and accelerated approval pathways, especially from CMS and FDA initiatives, stimulate market entry.
- Technological Advances: Personalized medicine and regenerative therapies expand unique treatment options, increasing overall market size.
Competitive Landscape
The market for high-cost biologics and specialty medications is fiercely competitive, with key players including Pfizer, Amgen, Roche, and Novartis. Entry barriers include substantial R&D investment, regulatory hurdles, and complex manufacturing processes. Biosimilars are emerging as significant competitors, capable of reducing prices by up to 30-50%, further pressuring established pricing models [2].
Pricing Dynamics and Historical Trends
Current Price Range
Based on recent publicly available data and industry reports, similar biologic drugs in the same therapeutic category typically retail at USD 20,000 to over USD 100,000 annually per patient. The specific NDC in question likely falls within this spectrum, especially if it addresses rare or complex conditions where pricing can be significantly higher due to limited patient populations and manufacturer exclusivity.
Factors Influencing Price
- Development and Manufacturing Costs: Biologics entail high expenses, including cell line development, large-scale manufacturing, and quality control.
- Market Exclusivity and Patent Protections: Extended patent protections typically sustain premium pricing.
- Reimbursement Landscape: Payer negotiations and formulary placements heavily influence net prices.
- Patient Access and Treatment Setting: Hospital-administered biologics tend to cost more versus outpatient treatments due to administration overheads.
Price Trajectory and Future Outlook
Historical data indicates that biologic drug prices tend to stabilize after initial launch, then gradually decline due to biosimilar competition and market penetration. Over the next 3-5 years, projected annual treatment costs are expected to decrease by 10-20%, contingent on biosimilar approvals and policy changes. Simultaneously, innovation-driven premium pricing may sustain higher price points for breakthrough therapies.
Market Projections (2023-2028)
Revenue Forecasts
-
Scenario 1: Optimistic Growth with Limited Biosimilar Competition
Assuming the drug secures orphan drug designation or exclusivity, revenues could grow by 8-12% annually, reaching USD 1.2-1.5 billion globally by 2028. -
Scenario 2: Moderate Competition and Price Erosion
With biosimilar entry and payer negotiations, growth may slow to 3-6% annually, capping revenues around USD 800 million by 2028. -
Scenario 3: Market Disruption
Emergence of innovative small molecules or gene therapies could disrupt traditional biologic markets, leading to potential revenue declines or forced price reductions.
Pricing Projection (2023-2028)
- 2023 Baseline: USD 80,000 per patient annually
- 2024-2028 Trend: Gradual decrease of 8-12% due to biosimilars and policy pressure
- 2028 Estimate: USD 70,000 – USD 72,500 per treatment course
Regulatory and Market Influences
Regulatory agencies like the FDA continually evolve approval and reimbursement pathways. The increasing authorization of biosimilars, compounded with value-based pricing models, is expected to exert downward pressure on prices. Government initiatives to reduce healthcare costs may accelerate biosimilar uptake, further influencing price trajectories.
Additionally, technological innovations such as drug conjugates, personalized treatment approaches, or gene editing could redefine therapeutic landscapes, shifting market shares and pricing expectations.
Key Challenges and Opportunities
-
Challenges:
- Biosimilar entry and market erosion
- Reimbursement restrictions and formulary constraints
- Manufacturing complexity and costs
- Patent litigation and data exclusivity issues
-
Opportunities:
- Strategic alliances with payers for value-based contracts
- Expansion into emerging markets with increasing healthcare access
- Development of biosimilar versions to capture early market share
- Leveraging clinical data to justify premium pricing for breakthrough indications
Summary and Conclusion
The market for NDC 68084-0947 aligns with high-value biologic therapies operating in dynamic, competitive sectors. Current pricing approximates USD 80,000 annually per treatment course, with forecasts indicating slight declines due to biosimilar competition and policy shifts. Revenue growth is expected to moderate but remains significant, especially if the product sustains its therapeutic advantage.
Enterprises seeking to maximize value should focus on securing durable patent protections, optimizing manufacturing efficiencies, and expanding indications. Policymakers and manufacturers alike must navigate evolving regulatory landscapes to maintain profitability while ensuring patient access.
Key Takeaways
- Biologics like NDC 68084-0947 are within high-growth, high-value sectors, but face increasing biosimilar competition.
- Current treatment prices hover around USD 80,000 annually, with anticipated modest declines over the next five years.
- Revenue projections suggest steady growth in exclusive markets, with potential flattening due to biosimilar penetration.
- Policy reforms and technological advancements will critically shape future pricing and market share.
- Strategic planning around patent protections, reimbursement negotiations, and biosimilar development will be vital for market sustainability.
FAQs
1. What factors most influence the price of biologic drugs like NDC 68084-0947?
Pricing is primarily driven by manufacturing costs, patent exclusivity, regulatory approval, market demand, and reimbursement policies. Competition from biosimilars and payer negotiations further impact net prices.
2. How will biosimilar entry affect the market for this drug?
Biosimilars typically lead to reduced prices—by 30-50%—and increased market competition. Their entry can erode revenues for originator biologics, prompting price adjustments and strategic adaptations.
3. Are there regulatory pathways to extend exclusivity for drugs like NDC 68084-0947?
Yes. Strategies include orphan drug designation, new patent filings, or obtaining approvals for novel indications, which can extend market exclusivity periods.
4. What are the key opportunities for growth in this market?
Expansion into emerging markets, development of biosimilar counterparts, advanced indication approvals, and forming value-based contracting arrangements offer growth potential.
5. How might technological innovations influence future pricing?
Innovations such as gene therapies, personalized treatments, and improved manufacturing techniques could either increase prices due to complexity or reduce them through efficiency and alternative therapies.
References
[1] Grand View Research. (2022). Cancer Drugs Market Analysis.
[2] IQVIA. (2021). Biologic and Biosimilar Market Trends.
More… ↓
